Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thromboxane A2 in postischemic acute compartmental syndrome

D Dabby1, F Greif, M Yaniv

  • 1Department of Surgery B, The Rabin Medical Center (Beilinson Campus), Petah-Tikva, Israel.

Archives of Surgery (Chicago, Ill. : 1960)
|September 28, 1998
PubMed
Summary

Thromboxane A2 significantly contributes to acute compartmental syndrome (ACS) ischemia-reperfusion injury. Inhibiting cyclooxygenase with aspirin reduced both thromboxane levels and compartmental pressures in a canine model.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crossing the border between epileptic and vascular pathology: a report of CACNA1A-related treatment-resistant hemiplegic migraine.

Journal of neurology·2023
Same author

Identification and characterization of a new ensemble of cometary organic molecules.

Nature communications·2022
Same author

Evaluation of daily environmental cleaning and disinfection practices in veterans affairs acute and long-term care facilities: A mixed methods study.

American journal of infection control·2022
Same author

Comparison of neutral outgassing of comet 67P/Churyumov-Gerasimenko inbound and outbound beyond 3 AU from ROSINA/DFMS.

Astronomy and astrophysics·2020
Same author

On the origin of molecular oxygen in cometary comae.

Nature communications·2018
Same author

Emerging technologies for home-based semen analysis.

Andrology·2017

Area of Science:

  • Orthopedics
  • Vascular Surgery
  • Pharmacology

Background:

  • Acute compartmental syndrome (ACS) is a severe condition characterized by increased pressure within a muscle compartment, leading to ischemia and potential tissue damage.
  • Ischemia-reperfusion injury is a complex process that occurs when blood supply is restored to tissues that have been deprived of oxygen.
  • The role of specific inflammatory mediators, such as thromboxane A2, in the pathogenesis of ACS is not fully understood.

Purpose of the Study:

  • To investigate the involvement of thromboxane A2 in the ischemia-reperfusion injury associated with ACS.
  • To determine if cyclooxygenase inhibitors can mitigate or prevent this injury.

Main Methods:

  • A canine model of ACS was established by applying a tourniquet to the hind limb for 2 hours.

Related Experiment Videos

  • Twelve dogs were divided into two groups: a control group (n=6) and a group pretreated with lysine-acetyl-salicylate (Lysoprim, a cyclooxygenase inhibitor) (n=6).
  • Blood thromboxane B2 levels and intracompartmental pressures were measured before tourniquet application and at multiple time points after deflation.

    • Main Results:

    • Following tourniquet release, intracompartmental pressures significantly increased in both groups, but to a lesser extent in the Lysoprim-treated group.
    • At 90 minutes and 24 hours post-deflation, compartment pressures were significantly lower (P<.01 and P<.001, respectively) in the Lysoprim group compared to controls.
    • Thromboxane B2 levels rose sharply in the control group but remained unchanged in the Lysoprim-treated group, indicating effective inhibition of thromboxane synthesis.

    Conclusions:

    • Thromboxane A2 plays a critical role in the ischemia-reperfusion injury observed in acute compartmental syndrome.
    • Administration of a cyclooxygenase inhibitor effectively reduces both thromboxane levels and the severity of compartmental hypertension in ACS.
    • These findings suggest that targeting thromboxane production may be a viable therapeutic strategy for managing ACS.